MAP4343
Spinal Cord Injury
About Mapreg
Mapreg is a private, clinical-stage biotech pioneering a novel class of CNS therapeutics called neuroplastogens, which aim to restore neuroplasticity at the core of neurons. Its lead asset, MAP4343, has received Orphan Drug Designation for Spinal Cord Injury and is positioned for Phase 2b/3 trials in Treatment-Resistant Depression (TRD). The company is backed by prestigious scientific founders, including Lasker Awardee Pr. Etienne Baulieu, and has raised approximately €20 million in equity, supplemented by significant non-dilutive grants from entities like the US Army and EUREKA.
View full company profileAbout Mapreg
Mapreg is a private, clinical-stage biotech pioneering a novel class of CNS therapeutics called neuroplastogens, which aim to restore neuroplasticity at the core of neurons. Its lead asset, MAP4343, has received Orphan Drug Designation for Spinal Cord Injury and is positioned for Phase 2b/3 trials in Treatment-Resistant Depression (TRD). The company is backed by prestigious scientific founders, including Lasker Awardee Pr. Etienne Baulieu, and has raised approximately €20 million in equity, supplemented by significant non-dilutive grants from entities like the US Army and EUREKA.
View full company profileAbout Mapreg
Mapreg is a private, clinical-stage biotech pioneering a novel class of CNS therapeutics called neuroplastogens, which aim to restore neuroplasticity at the core of neurons. Its lead asset, MAP4343, has received Orphan Drug Designation for Spinal Cord Injury and is positioned for Phase 2b/3 trials in Treatment-Resistant Depression (TRD). The company is backed by prestigious scientific founders, including Lasker Awardee Pr. Etienne Baulieu, and has raised approximately €20 million in equity, supplemented by significant non-dilutive grants from entities like the US Army and EUREKA.
View full company profileTherapeutic Areas
Other Spinal Cord Injury Drugs
| Drug | Company | Phase |
|---|---|---|
| MSC‑SCI | Advancells | Phase 1 |
| itNSCs | Stemedica Cell Technologies | Development |
| Spinal Cord Injury Program | BioAxone Biosciences | Clinical |
| Undisclosed Scaffold Program | Innervace | Pre-clinical |
| Q-Cells | Q Therapeutics | Research |
| APOSEC | Aposcience | Pre-clinical |
| NG004 | Neurimmune | Phase 1 |
| Perineline™ | NeuroSolv Therapeutics | Phase 1 |
| Nogo-A Receptor Blocking Antibody | NovaGo Therapeutics | Phase 1b |
| Spinal Cord Injury (SCI) Neural Bridge | Matricelf | Preclinical |